Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.

Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR.

Cancer. 2012 Nov 1;118(21):5302-9. doi: 10.1002/cncr.27450. Epub 2012 Apr 4.

2.

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.

Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou SH, Camidge DR.

Cancer. 2013 Jul 1;119(13):2383-90. doi: 10.1002/cncr.28089. Epub 2013 Apr 12.

3.

Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.

O'Bryant CL, Wenger SD, Kim M, Thompson LA.

Ann Pharmacother. 2013 Feb;47(2):189-97. doi: 10.1345/aph.1R002. Epub 2013 Feb 5. Review.

PMID:
23386065
4.

Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib.

Brosnan EM, Weickhardt AJ, Lu X, Maxon DA, Barón AE, Chonchol M, Camidge DR.

Cancer. 2014 Mar 1;120(5):664-74. doi: 10.1002/cncr.28478. Epub 2013 Nov 20.

5.

Hypogonadism related to crizotinib therapy: implications for patient care.

Ramalingam SS, Shaw AT.

Cancer. 2012 Nov 1;118(21):E1-2. doi: 10.1002/cncr.27561. Epub 2012 Apr 4. No abstract available.

6.

Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.

Rodig SJ, Shapiro GI.

Curr Opin Investig Drugs. 2010 Dec;11(12):1477-90. Review.

PMID:
21154129
7.

ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.

Scagliotti G, Stahel RA, Rosell R, Thatcher N, Soria JC.

Eur J Cancer. 2012 May;48(7):961-73. doi: 10.1016/j.ejca.2012.02.001. Epub 2012 Mar 6.

PMID:
22397764
8.

Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.

Sargis RM, Salgia R.

Am J Clin Oncol. 2015 Oct;38(5):442-7. doi: 10.1097/COC.0b013e3182a46896.

9.

Heart rate decrease during crizotinib treatment and potential correlation to clinical response.

Ou SH, Tong WP, Azada M, Siwak-Tapp C, Dy J, Stiber JA.

Cancer. 2013 Jun 1;119(11):1969-75. doi: 10.1002/cncr.28040. Epub 2013 Mar 15.

10.

[ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?].

Audigier-Valette C, Girard N, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlesi F.

Bull Cancer. 2014 Sep;101(9):823-31. doi: 10.1684/bdc.2014.1976. French.

PMID:
25299566
11.

Crizotinib for the treatment of non-small-cell lung cancer.

Timm A, Kolesar JM.

Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7. doi: 10.2146/ajhp120261.

PMID:
23686600
12.

Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.

Gastaud L, Ambrosetti D, Otto J, Marquette CH, Coutts M, Hofman P, Esnault V, Favre G.

Lung Cancer. 2013 Nov;82(2):362-4. doi: 10.1016/j.lungcan.2013.08.007. Epub 2013 Aug 15.

PMID:
24001942
13.

Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.

Awad MM, Lax TP, Slawski BR, Shaw AT.

J Thorac Oncol. 2014 Nov;9(11):1726-8. doi: 10.1097/JTO.0000000000000350.

14.

Treatment of ALK-positive non-small cell lung cancer.

Bang YJ.

Arch Pathol Lab Med. 2012 Oct;136(10):1201-4.

PMID:
23020724
15.

Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.

Park J, Yoshida K, Kondo C, Shimizu J, Horio Y, Hijioka S, Hida T.

Lung Cancer. 2013 Sep;81(3):495-6. doi: 10.1016/j.lungcan.2013.06.017. Epub 2013 Jul 25.

PMID:
23891512
16.

Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007).

Ou SH, Tang Y, Polli A, Wilner KD, Schnell P.

Cancer Med. 2016 Apr;5(4):617-22. doi: 10.1002/cam4.622. Epub 2016 Jan 28.

17.

Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.

Tartarone A, Gallucci G, Lazzari C, Lerose R, Lombardi L, Aieta M.

Future Oncol. 2015;11(14):2043-8. doi: 10.2217/fon.15.47. Review. Erratum in: Future Oncol. 2015 Sep;11(18):2612.

PMID:
26198834
18.

Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.

de Castro-Carpeño J, Perona R, Belda-Iniesta C.

Clin Transl Oncol. 2011 Nov;13(11):774-9. doi: 10.1007/s12094-011-0732-8. Review.

PMID:
22082640
19.

Crizotinib-associated erythema multiforme in a lung cancer patient.

Sawamura S, Kajihara I, Ichihara A, Fukushima S, Jinnin M, Yamaguchi E, Kohrogi H, Ihn H.

Drug Discov Ther. 2015 Apr;9(2):142-3. doi: 10.5582/ddt.2015.01019.

20.

Crizotinib-induced pancreatic pseudocyst: a novel adverse event.

Ishida H, Ichikawa W, Sasaki Y.

BMJ Case Rep. 2015 Sep 8;2015. pii: bcr2015211556. doi: 10.1136/bcr-2015-211556.

PMID:
26351314

Supplemental Content

Support Center